MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Ovid therapeutics Inc

Închisă

SectorSănătate

0.54 17.39

Rezumat

Modificarea prețului

24h

Curent

Minim

0.46

Maxim

0.56

Indicatori cheie

By Trading Economics

Venit

-982K

-10M

Vânzări

54K

130K

Marjă de profit

-7,873.077

Angajați

23

EBITDA

-1.8M

-12M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+489.58% upside

Dividende

By Dow Jones

Următoarele câștiguri

12 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

3.3M

28M

Deschiderea anterioară

-16.85

Închiderea anterioară

0.54

Sentimentul știrilor

By Acuity

50%

50%

154 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 iul. 2025, 21:01 UTC

Câștiguri

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

18 iul. 2025, 20:46 UTC

Câștiguri

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 iul. 2025, 20:39 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 iul. 2025, 20:36 UTC

Câștiguri

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 iul. 2025, 20:16 UTC

Achiziții, Fuziuni, Preluări

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 iul. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 iul. 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 iul. 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 iul. 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 iul. 2025, 18:24 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 iul. 2025, 18:19 UTC

Câștiguri

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 iul. 2025, 18:11 UTC

Achiziții, Fuziuni, Preluări

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 iul. 2025, 18:11 UTC

Câștiguri

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 iul. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 iul. 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 iul. 2025, 16:28 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 iul. 2025, 16:22 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Energy & Utilities Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

18 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 iul. 2025, 16:04 UTC

Câștiguri

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 iul. 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 iul. 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 iul. 2025, 15:47 UTC

Market Talk
Câștiguri

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparație

Modificare preț

Ovid therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

489.58% sus

Prognoză pe 12 luni

Medie 2.83 USD  489.58%

Maxim 4 USD

Minim 1.5 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOvid therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

5

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.275 / 0.33Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

154 / 376 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.